PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
X. Le(The University of Texas MD Anderson Cancer Center), J. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Óscar Juan(Hospital Universitari i Politècnic La Fe), Steven Yea(Array BioPharma (United States)), H. Hayashi(Kindai University Hospital), Tao Hu(Hunan Normal University), J. Zhang(Anhui Provincial Hospital), B. Gao(Blacktown & Mount Druitt Hospital), X. Li(First Affiliated Hospital of Zhengzhou University), Y. Zhao(Henan Cancer Hospital), M. Pérol(Centre Léon Bérard), A. Spira(Virginia Cancer Specialists), Yong Jiang(Peking University), Julien Mazières(Université Toulouse III - Paul Sabatier), Satoru Kitazono(The Cancer Institute Hospital), M. Kowanetz(Array BioPharma (United States)), Wing Leung(KK Women's and Children's Hospital), D. Planchard(Institut Gustave Roussy), John Hsu(Kaiser Permanente), N. Leighl(Princess Margaret Cancer Centre), Jonathan W. Riess(University of California Davis Medical Center), Nicola Baio(Array BioPharma (United States)), Song Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian‐An Huang(Soochow University), S. Gadgeel(Henry Ford Health System), L. Musib(Array BioPharma (United States)), Yu Yang(Harbin Medical University), A.J. de Langen(The Netherlands Cancer Institute)
Cited by 14
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k